All In Biotech

Drug Trial Radar · NCT07393334

Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive

Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive, on Semen Volume and Sperm Count in Normal Men: A Double-Blind, Placebo-Controlled Trial

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Dec 2, 2025

Primary completion

Mar 2026

Study completion May 2026

Sponsor

Lead sponsor
Next Life SciencesIndustry
Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

NLS-133-CLIN001 is a Phase 2a study designed to assess the safety, tolerability, and effects of NLS-133 (combination of two FDA-approved agents) compared to an active control (FDA-approved pharmacologic agent) or placebo on semen volume and sperm count in 10 in healthy men. Participants will be randomized in a crossover design to receive a single dose of NLS-133, an active control or placebo either 90 or 180 minutes prior to collection of semen. Sperm parameters measured will be count, motility and morphology. A brief questionnaire will be completed by each subject during each treatment cycle that addresses orgasm and ejaculation quality. Safety monitoring will include adverse event reporting, laboratory assessments, and vital signs.

Conditions

  • Male Contraception
  • Semen Volume
  • Sperm Motility

Interventions

  • NLS-133Drug

    NLS-133 is the primary experimental arm of the study

  • PlaceboDrug

    Double placebo arm of the study

  • Active Comparator #1Drug

    Active control arm of study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Semen volume (mL)Time frame: 90 and 180 minutes for each treatment cycle
  2. Sperm count (millions/mL)Time frame: 90 and 180 minutes for each treatment cycle

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Population Center for Research in Human Reproduction and Departments of Medicine, University of Washington

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.